中红医疗：拟使用不超过20亿元的闲置自有资金购买理财产品

Group 1 - The core point of the article is that Zhonghong Medical announced the approval of an investment plan for idle funds, allowing the company and its subsidiaries to invest up to 2 billion RMB in low-risk financial products for the year 2026 [1] Group 2 - The investment plan aims to ensure that the company meets its normal operational funding needs while utilizing idle funds effectively [1] - The approved financial products are characterized by high safety, good liquidity, stability, and controllable risks [1] - The investment will be valid for the year 2026 and will take effect after the first extraordinary shareholders' meeting of the company in 2026 [1]